Clinical Trial

TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC

Name: TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC — clinical trial record (NCT07498595)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Early Phase 1

View on ClinicalTrials.gov →

Summary

This is a single-arm study designed to evaluate the safety and efficacy of TILs combined with third-generation EGFR-TKIs therapy for patients with EGFR-mutant NSCLC resistant to TKI.

Trial Details

NCT Number	NCT07498595
Lead Sponsor	Tianjin Medical University General Hospital
Conditions	EGFR-TKI-resistant Non-Small Cell Lung Cancer
Enrollment	50 participants
Start Date	2026-03-31
Primary Completion	2028-03-31 (estimated)
Study Completion	2030-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-03-27